Pharmacological targeting of xCT/system Xc- to modulate temozolomide sensitivity in glioma and glioblastoma preclinical models: a focused systematic review

Background

Resistance to temozolomide (TMZ) remains a major barrier in glioblastoma treatment. The cystine/glutamate antiporter system Xc-, mainly through its xCT/SLC7A11 light-chain subunit, supports cystine uptake, glutathione synthesis and redox balance, making it a biologically plausible target for modifying TMZ response. This focused systematic review evaluated whether pharmacological xCT/system Xc--relevant inhibition enhances TMZ sensitivity in glioma/glioblastoma preclinical models.